Indeed, we found that promoters, CTCF sites, and enhancers could all exhibit characteristics of epigenetic activation in MCF7 breast cancer cells (Fig. 4A) and in PC3 prostate cancer cells (Fig. 4B). The gene discussed is CTCF; the disease is breast carcinoma.